To summarise the evidence on the associations between body mass index (BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio (WHR), and risk of lympho-hematopoietic cancers.
Our results revealed that general adiposity in adulthood and early adulthood, and greater height may increase the risk of almost all types of lympho-hematopoietic cancers and this adds to a growing body of evidence linking body fatness to several types of cancers.
Introduction
Overweight and obesity are a global health problem. During the last forty years, the number of obese adults increased from 100 million in 1975 (69 million women, 31 million men) to 671 million in 2016 (390 million women, 281 million men) [1] . Excess weight and obesity have been linked to several chronic diseases including cardiovascular disease [2, 3] , diabetes [3] and many types of cancersincluding lympho-hematopoietic cancers [4] .
The age standardized incidence rates worldwide (per 100 000 inhabitants) were estimated of 1.0 for HL, 6.7 for NHL, 2.1 for multiple myeloma and 5.7 for leukaemia in 2018 [5] .
Although, lympho-hematopoietic cancers are not as frequent as other cancers such as lung, breast, colorectal and prostate cancers, it is very important to investigate their association with overweight and obesity, which are the major public health issues. Consequentlyfindings can add to the existing literature about the importance of lifestyle modification specifically weight management in prevention of haematological cancer incidence and mortality [4] .
Previous meta-analyses published up to 2014, showed that greater BMI may increase the risk of HL [6] , NHL [6] , DLBCL [7] , myeloma [8] and leukaemia [9] . Since the publication of these meta-analysis, several additional large prospective studies with large number of cases have been published [10] [11] [12] [13] [14] [15] [16] . The accumulated evidence has greatly enhanced the investigation of how these modifiable risk factors influence the development of the many different types of lympho-haematopoietic cancers. Moreover, whether BMI in early adulthood (age 18-21 years), height, and abdominal obesity increase the risk of lymphohaematopoietic cancers, has not been summarized in a meta-analysis. Therefore, we conducted a systematic literature review and meta-analysis of prospective studies of BMI, BMI in early adulthood, height, weight, waist circumference and waist to hip ratio, and the risk of lymphoma, myeloma and leukaemia, and their main types to provide an up-to-date and comprehensive assessment of the existing evidence. We aimed to clarify the strength and shape of dose-response relationship between the general and abdominal adiposity and lympho-haematopoietic cancers and investigate any potential differences by sub-sites, sex, geographical locations, size of cohort, number of cases, years of follow up, exposure assessment methods, and adjustment for potential confounders.
Methods

Search strategy and inclusion criteria
The CUP team at Imperial College London searched in PubMed for studies on anthropometric measures including BMI, BMI in early adulthood (age 18-21), height, weight, waist circumference and waist to hip ratio, and lympho-hematopoietic cancer risk up to December 2017. The specific search criteria and the review protocol can be seen in supplementary materials.
Study selection
Our study selection was restricted to cohort (prospective, retrospective, case-cohort or nested case-control studies) studies which investigated the link between anthropometric measures and lympho-hematopoietic cancer risk and mortality, and reported estimates of the relative risk (RR) (e.g., hazard ratio, risk ratio or odds ratio) and 95% confidence intervals (CIs) for the exposures of interest (BMI, BMI in early adulthood (aged 18-21 years), weight, waist circumference, and waist-to-hip ratio). In case of studies reporting only categorical results, number of cases and denominator data (person-years of follow-up or number of subjects) were required for inclusion in the meta-analysis. If there were multiple publications from the same study, the newest publication which included the largest number of cases was selected.
Data extraction
We extracted the following data from each study: authors, year of publication, country of origin, cancer type, length of study and loss of follow up, sample size, numbers of cases and population at risk/controls, age, sex and other characteristics, anthropometric measures, relative risks and 95% confidence intervals or P-values for each exposure category and adjustment variables. A second reviewer checked at least 10% of the work.
Statistical analysis
We calculated the summary RRs and 95% CIs using random effect models which takes into account heterogeneity between studies [17] . Q and I² statistics were used to determine heterogeneity [18] , potential sources of which were explored in stratified analyses by sex, geographical location, exposure assessment methods, years of follow-up, number of cases, size of cohort, and adjustments for confounders including alcohol consumption, smoking, and physical activity.
We used RR estimates and CIs for continuous increments directly from the articles if provided, and for studies that only reported categorical data, dose-response associations and 95% CIs were derived using generalized least-squares for trend estimation [19] , which required the RRs and CIs associated to at least three categories of anthropometric measures, and number of cases and non-cases or person years of follow up per category to be available.
If only the total number of cases or person years was reported in the articles, and the exposure was categorised in quantiles, the distribution of persons or person years was calculated by dividing the total number of persons or person years by the number of quantiles. We used the mean or median values per each anthropometric category if available in the articles, or the midpoint was calculated for studies that only reported a range by category. If the range of the highest or lowest category was open-ended, its width was assumed to be the same as the adjacent category. In case of close-ended lowest and highest categories with category widths substantially greater than those of the middle-categories (e.g. highest category of kg/m 2 of BMI), the Chêne and Thompson [20] method was used to estimate the midpoints. The Hamling's method was used to recalculate the relative risk estimates when the first category was not used as reference [19] . If the results were reported for men and women separately, they were combined using a fixed effects meta-analysis before being pooled with other studies in linear, but not non-linear, analyses.
We assessed small-study effects, such as publication bias, by using funnel plots and Egger's test [21] .
We assessed a potential nonlinear dose-response association between anthropometric measures and risk of lympho-hematopoietic cancers when we had ≥ 3 studies by calculating restricted cubic splines for each study, using three fixed knots at 10 th , 50 th , and 90 th percentiles of distribution of the exposure to account for a wider exposure range while minimising any potential impact from the outliers in the tails, and combined them by using multivariate meta-analysis. In order to be eligible for this procedure, at least three categories of exposure needed to be reported by a given study.
For all analyses, the results of each article with the most comprehensive adjustment for confounders were included. A two-tailed p<0.05 was considered statistically significant.
Stata version 13.1software (StataCorp, College Station, TX) was used.
Results
Study selection is shown in the flowchart (Figure 1 ).
Out of 65 publications, 27 studies (37 publications [10] [11] [12] [13] [14] [15] ) on blood cancers risk (lymphoma, leukaemia and myeloma) and 68 studies (10 publications including 1 Pooled analysis of 39 cohorts and 1 Pooled analysis of 20 cohort studies [22, 46, 46, [50] [51] [52] [53] 53, 54, 54, 55, 55, 56, 56, 57, 57] )on blood cancers mortality (lymphoma, leukaemia and myeloma) were included in the dose-response meta-analyses. The characteristics of the included studies are shown in supplementary materials.
BMI and lymphomas risk and mortality
The summary RR per 5 kg/m 2 increase of BMI was 1.12 (95%CI=1.05-1.20, I 2 =1.9%, P heterogeneity =0.40) for HL (5 studies [12, 36, 39, 40, 58] , Figure 2A ), 1.05(95%CI: 1.03-1.08, I 2 =45%, P heterogeneity =0.02) for NHL (20 studies [10] [11] [12] 23, 24, [27] [28] [29] [30] [31] 33, 34, 36, [39] [40] [41] [42] 58] , Figure 3 ), 1.11, 95%CI=1.05-1.16, I 2 =16%, P heterogeneity =0.29) for DLBCL (18 studies [11, 12, 24, 26, 29, 30, 32, 33, 36, 42, 48] , supplementary Figure 1 ), and 1.03 (95%CI=0.98-1.09, I 2 =3%, P heterogeneity =0.41) for FL (19 studies [11, 12, 24, 26, 29, 30, 32, 33, 36, 42, 48] , supplementary Figure 2 There was no evidence of publication bias in any of the analysis (p-value for Egger's test= 0.24 for HL; 0.12 for NHL (incidence); 0.10 for NHL (mortality) 0.17 for DLBCL;0.37 for FL).
There was evidence of nonlinearity of the association of BMI and HL (p for non-linearity < 0.001). The risk increase was observed in the range of BMI above 32 kg/m 2 ( Figure 2B ).
However, there was no evidence of non-linearity association between BMI and NHL (p for non-linearity=0.66) ( Supplementary Figure 4) , DLBCL (p for non-linearity=0.50) (Supplementary Figure 5 ), and FL (p for non-linearity=0.58) (Supplementary Figure 6 ).
Moreover, there was no evidence of nonlinearity (p for non-linearity=0.66) between BMI and NHL mortality ( Supplementary Figure 7) .
BMI and multiple myeloma (MM) risk and mortality
The summary RR per 5 kg/m 2 increment of BMI was 1.06 (95%CI=1.03-1.10, I 2 =13%, P heterogeneity =0.31, 23 studies [10, 12, 14, 15, 26, 27, [30] [31] [32] 37, 40, 43, 44, 59, 60] There was no evidence of nonlinearity for the association of BMI and MM risk (p for non-linearity=0.50) ( Supplementary Figure 9 ), and mortality (p for non-linearity=0.33) (Supplementary Figure 10 ).
BMI and leukaemia risk and mortality
The summary RR per 5 kg/m 2 increment of BMI was 1.09 (95%CI=1.03-1. 15 [13, 30, 31, 39, 47, 58] ) ) for CLL ( Figure   5 ).
The summary RR per 5 kg/m 2 increment of BMI was 1.17 (95%CI=1.05-1.30, I 2 =49%, P heterogeneity =0.06, 46 studies [45, 46, 51, 52, 54, 56, 57, 62] for leukaemia mortality (Supplementary Figure 11 ).
There was no evidence of publication bias in any of the analyses (p-value for Egger's test =0.97 for leukaemia; 0.24 for AML; 0.68 for CML; 0.36 for CLL).
There was no statistical evidence of departure from linearity (p-values for non-linearity tests were 0.60 for leukaemia risk; 0.46 leukaemia mortality; 0.68 for AML and 0.32 for CLL ( Supplementary Figures 12, 13 , 14 and 15, respectively).
BMI in early adulthood (age 18-21 years) and lymphoma risk
The summary RR per 5 kg/m 2 increment of BMI was 1.12 (95%CI=1.05-1.19, I 2 =43%, P heterogeneity =0.10) for NHL (7 studies [11, 23, 24, 29, 33, 42] Figure 18 ).
There was no evidence of publication bias in most of the analyses (p-value for Egger's test =0.36 for NHL; 0.74 for DLBCL). However, there was an evidence of publication bias in the FL analysis (p-value for Egger's test =0.05). Visual inspection of the funnel plot showed moderate asymmetry, which appeared to be driven by the strong and relatively precise association reported in the NHS study [11] .
There was some evidence of nonlinearity of the association of early adulthood BMI and NHL (p for non-linearity=0.05), with steady risk increase within the BMI range of approximately 15-23 kg/m 2 , with gradual flattening of the slope with increasing BMI thereafter (Supplementary Figure 19 ).
There was no evidence of nonlinearity of the association of early adulthood BMI and DLBCL (p for non-linearity=0.83) ( Supplementary Figure 20) , and FL (p for non-linearity=0.60) (Supplementary Figure 21) .
Height
Height and lymphoma risk
The summary RR per per 5 cm increment of height was 1.07 (95%CI=1.05-1.10, I 2 =70%, P heterogeneity <0.01) for NHL(13 studies [11, 12, [23] [24] [25] [28] [29] [30] 33, 42, 58, 63] ) (Table 1 and supplementary Figure 22 ), 1.10 (95%CI=1.06-1.15, I 2 =41%, P heterogeneity 0.09) for DLBCL (10 studies [11, 12, 24, 29, 30, 32, 33, 36, 42, 48] ) (Table 1 and supplementary Figure 23 ), and 1.09 (95%CI=1.06-1.13, I 2 =0%, P heterogeneity =0.54) for FL(10 studies [11, 12, 24, 29, 30, 33, 36, 42, 48] ) (Table 1 and supplementary Figure 24 ).
There was no evidence of publication bias in any of analysis (p-value for Egger's test= 0.57 for NHL; 0.48 for DLBCL; 0.64 for FL).
There was no evidence of nonlinearity of the association between height and NHL (p for non- 
Height and multiple myeloma risk
The summary RR per per 5 cm increment of height was 1.05 (95%CI=1.02-1.08, I 2 =1%, P heterogeneity =0.42, 8 studies [12, 15, 25, 30, 32, 43, 63, 64] ) (Table 1 and supplementary Figure   28 ).There was no evidence of publication bias (p-value for Egger's test= 0.64).
There was no evidence of nonlinearity of the association of height and MM (p for non-linearity=0.17) ( Supplementary Figure 29 ).
Height and leukaemia risk
The summary RR per per 5 cm increment of height was 1.07 (95%CI=1.03-1.11, I 2 =51%, P heterogeneity =0.06, 7 studies [12, 13, 25, 47, [63] [64] [65] ) (Table 1 and supplementary Figure 30 ).
There was no evidence of publication bias (p-value for Egger's test= 0.24).
There was no evidence of nonlinearity of the association of height and Leukaemia (p for non-linearity=0.76) ( Supplementary Figure 31) .
Weight
Weight and lymphoma risk
The summary RR per 5 kg increment of weight was 1.02 (95%CI=0.99-1.06, I 2 =70%, P heterogeneity =0.01) for NHL (5 studies [24, 28, 29, 33, 42] ) ( Supplementary Figure 32 ), 1.03 (95%CI=0.98-1.07, I 2 =22%, P heterogeneity =0.89) for DLBCL (6 studies [24, 29, 32, 33, 42, 48] ) ( Supplementary Figure 33) , and 1.00 (95%CI=0.96-1.04, I 2 =7%, P heterogeneity =0.37) for FL (6 studies [24, 29, 32, 33, 42, 48] ) ( Supplementary Figure 34) (Table 1) .
There was no evidence of publication bias (the p-value for Egger's test= 0.56 for NHL; 0.89 for DLBCL; 0.40 for FL).
There was no evidence of nonlinearity of the association of weight and NHL (p for non- Figure 37 ).
Waist circumference
Waist circumference and lymphoma risk
The summary RR per 5 cm increment of waist circumference was 1.06 (95%CI=0.97-1.15, I 2 =0%, P heterogeneity =0.92, 5 studies [11, 24, 32, 48] ) for DLBCL and 1.00 (95%CI=0.92-1.09, I 2 =0%, P heterogeneity =0.80, 5 studies [11, 24, 32, 48] ) for FL ( Supplementary Figure 38 and 39 ).
There were not enough studies to conduct the non-linear analysis.
Waist circumference and multiple myeloma risk
The summary RR per 5 cm increment of waist circumference was 1.01 (95%CI=0.97-1.05, I 2 =79.8%, P heterogeneity <0.001, three studies [32, 43, 48] ) ( Table 1 and supplementary Figure   40 ).
Waist to hip ratio
Waist to hip ratio and lymphoma risk
The summary RR per 0.1 unit increment of waist to hip ratio was 1.12 (95%CI=1.01-1.26, I 2 =0%, P heterogeneity =0.71) for DLBCL (7 studies [11, 24, 32, 36, 42, 48] ) (Supplementary Figure   41 ), and 0.98 (95%CI=0.86-1.11, I 2 =0%, P heterogeneity =0.84) for FL (7 studies [11, 24, 32, 36, 42, 48] ) ( Supplementary Figure 42 ) (Table1).
There was no evidence of publication bias in any of analysis (the p-value for Egger's test= 0.61 for DLBCL; 0.17 for FL).
There was no evidence of nonlinearity of the association of WHR and DLBCL (p for nonlinearity = 0.45) ( Supplementary Figure 43) , and FL (p for non-linearity = 0.75) ( Supplementary Figure 44) .
Subgroup analyses
The observed associations in the main analysis persisted in most subgroup analyses defined by sex, geographical locations, exposure assessment methods, duration of follow-up, cohort size, number of cases and adjustments for potential confounding factors including alcohol consumption, smoking and physical activity, although the results were not always statistically significant ( Table 1 and Supplementary tables). There were no apparent differences between the subgroups that could explain the moderate heterogeneity observed in the analyses of BMI and risk of NHL and AML and leukaemia mortality; BMI in early adulthood and NHL; and height and NHL. For the analysis of BMI and leukaemia, weaker positive associations were observed in the studies in men than studies in women. For the analyses of height and DLBCL and leukaemia, null associations were observed in the studies in men, which were also studies with medium-size of cohort and >20 years of follow-up. Other factors did not appear to explain the observed heterogeneity.
Study quality
In most of the included studies, cases were ascertained via record linkage to cancer and death registries. All the studies were adjusted at least for age and sex, but only some studies were adjusted for confounders including alcohol consumption, smoking and physical activity; and unadjusted studies more often showed statistically significant results on average than adjusted studies. Most of the included studies used self-reported measurements.
Most of the included studies did not report loss to follow up and only few studies reported a follow-up that was almost complete (≤1%) which include 5 studies for BMI [24, 28, 43, 58, 61] , and height [24, 25, 28, 43, 58] , 2 studies for weight [24, 28] , and 1 study [24] for BMI in early adulthood, waist to hip ratio and waist circumference.
Discussion
This study provides the most comprehensive and up-to-date summary estimates of the association between all anthropometry factors including BMI, BMI in early adulthood, height, weight, waist circumference and waist to hip ratio and risk of lympho-hematopoietic cancers including lymphomas, multiple myeloma, and leukaemia.
Higher BMI showed to be associated with increased risk of all included type of lymphohematopoietic cancers, except for FL, for which no significant association was observed. The observed increased risk ranged from 4% in CLL to 13% in AML and CML, respectively, per 5 kg/m 2 . Moreover, higher BMI in early adulthood (age 18-21) showed to increase the risk of NHL, FL and DLBCL cancers by 12%, 19% and 22%, respectively.
Our main findings on BMI, are consistent with previous published meta-analysis which all showed greater BMI is associated with increased risk of HL [6] , NHL [6] , DLBCL [7] , multiple myeloma [8] and leukaemia [9] . However, our meta-analysis included higher number of studies and we did separate analysis for BMI in early adulthood. We also investigated the associations by subgroup analyses, including sex, geographical locations, size of cohort, number of cases, years of follow up, exposure assessment methods, and adjustment for potential confounders for all types of lympho-hematopoietic cancers, providing a more comprehensive estimate of the effects of adiposity in the incidence of lympho-hematopoietic cancers.
The analysis on height also revealed that greater height was associated with increased risk of lymphomas, multiple myeloma and leukaemia, and the increased risks ranged from 5% in multiple myeloma to 10% in DLBCL, respectively.
Our results on abdominal obesity and the risk of lympho-hematopoietic cancers using WHR and waist circumference measures showed an increased risk of DLBCL by12% with higher WHR, and no association was found between higher waist circumferences and risk of multiple myeloma which could be due to limited number of studies (n=3).
Several risk factors of haematological malignancies have been identified including radiation, chemicals (e.g. benzene for AML [66] ), viruses (e.g. Epstein Barr virus for adult HL [67] ), HIV infection [68] , hepatitis C virus for NHL [69] and some conditions such as autoimmune disease and chronic inflammatory conditions [7, 9] . However, less is known about lifestyle factors. There are several potential mechanisms whereby excess body fatness may increase the risk of haematological malignancies [70, 71] . Body fatness and obesity leads to changes in circulating levels of adipocytokines, including adiponectin, resistin, and leptin, and these hormones can affect insulin resistance, immunity, and inflammation [7, [70] [71] [72] [73] [74] [75] . Leptin has proinflammatory properties and promotes the growth of some cancer cells, and it stimulates the proliferation of normal haematopoietic cells and circulating monocytes producing proinflammatory cytokines [71, 75] . Also, obesity may increase the risk of lymphoma by affecting insulin resistance and hyper-insulinemia which leads to increased bio-available insulin-like growth factor-I (IGF-I) [71] . IGF-I is known to act as a growth factor which promotes cell proliferation and inhibits apoptosis through IGF-I receptor-mediated signalling mechanisms in various tissues, including haematopoietic cells [71] .
Our meta-analysis has some limitations that should be taken into account when interpreting the results. Moderate proportions of between-study heterogeneity were observed in some analyses and remained largely unexplained by the factors explored in the current study. In some subgroup analyses, the number of studies was too small to allow full exploration of heterogeneity. Uncontrolled confounding maybe an issue, particularly for BMI and AML, where smoking which is linked to body weight [76] has been shown to increase the risk of AML [77] It is possible that our results could be biased due to the fact that most of studies used selfreported BMI rather than measured, and there is an observed tendency for overweight and obese people to overestimate height and underestimate weight compared to normal weight individuals. However, when we analysed the data according to measured or self-reported anthropometry the results were mostly similar, with confidence intervals overlapping.
Another limitation of the study is that not all studies separated the haematopoietic cancers according to the current WHO classification system. For instance, the most current lymphoid malignancy classification system typically considers CLL to be the same cancer as SLL and as such, CLL/SLL is considered as non-Hodgkin lymphoma. Some of the studies included in the meta-analysis for NHL include CLL and others may also include multiple myeloma. This potential source of heterogeneity could not be addressed. Also, there may be an overlapping of some cancers across groups.
A strength of our study are as follows:(i) inclusion of large studies with prospective design, which reduces the possibility of recall or selection bias (ii) large number of studies with relatively long duration of follow up and large number of cases that increase the statistical power of our analysis, and (iii) the nonlinear analyses which allowed us to examine the shape of the dose-response relationships.
Conclusion
In conclusion, our results revealed that greater BMI in adulthood as well as greater height may increase the risk of lympho-hematopoietic cancers and this adds to a growing body of evidence linking body fatness to several types of cancers. 
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